Darius Kharabi Sells 2,021 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

KALA BIO, Inc. (NASDAQ:KALA) insider Darius Kharabi sold 2,021 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.63, for a total transaction of $15,420.23. Following the completion of the transaction, the insider now owns 67,807 shares of the company’s stock, valued at approximately $517,367.41. The trade was a 2.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

KALA BIO Stock Performance

Shares of KALA stock traded up $0.16 during trading hours on Tuesday, reaching $7.69. 45,377 shares of the company’s stock were exchanged, compared to its average volume of 105,019. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 2.15. KALA BIO, Inc. has a 1 year low of $4.21 and a 1 year high of $9.25. The company’s 50 day moving average is $6.71 and its two-hundred day moving average is $6.32. The company has a market cap of $35.45 million, a P/E ratio of -0.62 and a beta of -2.11.

KALA BIO (NASDAQ:KALA) last posted its earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share for the quarter, beating the consensus estimate of ($2.43) by $0.50. Equities research analysts anticipate that KALA BIO, Inc. will post -10.84 EPS for the current fiscal year.

Hedge Funds Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP purchased a new position in shares of KALA BIO, Inc. (NASDAQ:KALA) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO makes up about 1.0% of SR One Capital Management LP’s holdings, making the stock its 9th biggest holding. SR One Capital Management LP owned approximately 15.76% of KALA BIO at the end of the most recent quarter. Hedge funds and other institutional investors own 24.61% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of KALA BIO in a research note on Friday, November 15th.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.